Savara Pharmaceuticals (SVRA:NASDAQ) Investor Relations Material

Overview

Austin-based Savara Inc., a clinical stage biopharmaceutical firm, is zeroing in on rare respiratory diseases with its innovative approach. The company's frontrunner is its star candidate, molgramostim, comprising an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development stage exclusively for treating the incurable autoimmune pulmonary alveolar proteinosis.

Annual Reports

Frequently Asked Questions

What is Savara Pharmaceuticals's ticker?

Savara Pharmaceuticals's ticker is SVRA

What exchange is Savara Pharmaceuticals traded on?

The company's shares trade on the NASDAQ stock exchange

Where are Savara Pharmaceuticals's headquarters?

They are based in Austin, Texas

How many employees does Savara Pharmaceuticals have?

There are 11-50 employees working at Savara Pharmaceuticals

What is Savara Pharmaceuticals's website?

It is https://savarapharma.com/

What type of sector is Savara Pharmaceuticals?

Savara Pharmaceuticals is in the Healthcare sector

What type of industry is Savara Pharmaceuticals?

Savara Pharmaceuticals is in the Biotechnology industry

Who are Savara Pharmaceuticals's peers and competitors?

The following five companies are Savara Pharmaceuticals's industry peers:

- Interpace Biosciences, Inc.

- Patrys Limited

- Jounce Therapeutics

- ACADIA Pharmaceuticals

- Anika Therapeutics